ライフサイエンスコーパス: velpatasvir

1 atasvir-voxilaprevir and 90% with sofosbuvir-velpatasvir.

2 er 12 weeks of treatment with sofosbuvir and velpatasvir.

3 sofosbuvir combined with the NS5A inhibitor velpatasvir.

4 ng those who received 24 weeks of sofosbuvir-velpatasvir.

5 of those who received 24 weeks of sofosbuvir-velpatasvir.

6 -dose combination of sofosbuvir (400 mg) and velpatasvir (100 mg) once daily for 12 weeks, sofosbuvir

7 ll patients received sofosbuvir (400 mg) and velpatasvir (100 mg) plus GS-9857 (100 mg) once daily.

8 velpatasvir, 25 mg, and 100% (28 of 28) with velpatasvir, 100 mg, for genotype 1; 93% (25 of 27) in b

9 velpatasvir, 25 mg, and 95% (21 of 22) with velpatasvir, 100 mg, for genotypes 2, 4, 5, and 6.

10 velpatasvir, 100 mg; and 81% (25 of 31) with velpatasvir, 100 mg, plus ribavirin.

11 velpatasvir, 100 mg; and 88% (23 of 26) with velpatasvir, 100 mg, plus ribavirin.

12 Twelve weeks of sofosbuvir, 400 mg, and velpatasvir, 100 mg, was well-tolerated and resulted in

13 , 25 mg, plus ribavirin; 90% (26 of 29) with velpatasvir, 100 mg; and 81% (25 of 31) with velpatasvir

14 , 25 mg, plus ribavirin; 88% (23 of 26) with velpatasvir, 100 mg; and 88% (23 of 26) with velpatasvir

15 ir-voxilaprevir (163 patients) or sofosbuvir-velpatasvir (151 patients) for 12 weeks.

16 patients who received 12 weeks of sofosbuvir-velpatasvir, 16% of those who received 12 weeks of sofos

17 part A, SVR12 rates were 96% (26 of 27) with velpatasvir, 25 mg, and 100% (28 of 28) with velpatasvir

18 oups for genotype 3; and 96% (22 of 23) with velpatasvir, 25 mg, and 95% (21 of 22) with velpatasvir,

19 with velpatasvir, 25 mg; 88% (22 of 25) with velpatasvir, 25 mg, plus ribavirin; 88% (23 of 26) with

20 with velpatasvir, 25 mg; 83% (25 of 30) with velpatasvir, 25 mg, plus ribavirin; 90% (26 of 29) with

21 type 1, SVR12 rates were 87% (26 of 30) with velpatasvir, 25 mg; 83% (25 of 30) with velpatasvir, 25

22 type 2, SVR12 rates were 77% (20 of 26) with velpatasvir, 25 mg; 88% (22 of 25) with velpatasvir, 25

23 andomly assigned to sofosbuvir, 400 mg, with velpatasvir, 25 or 100 mg, for 12 weeks.

24 randomly assigned to sofosbuvir, 400 mg, and velpatasvir, 25 or 100 mg, with or without ribavirin for

25 ients who received treatment with sofosbuvir-velpatasvir, 34% had HCV genotype 1a, 19% genotype 1b, 1

26 All patients received sofosbuvir-velpatasvir (400 mg/100 mg fixed-dose combination tablet

27 tember 1, 2015, patients received sofosbuvir-velpatasvir (400 mg/100 mg in a fixed-dose combination)

28 ty of a fixed-dose combination of sofosbuvir-velpatasvir (400 mg/100 mg) plus weight-adjusted ribavir

29 cohort 2, SVR12 rates were 58% with 25 mg of velpatasvir, 84% with 25 mg of velpatasvir plus ribaviri

30 patients who received 12 weeks of sofosbuvir-velpatasvir, 94% (95% CI, 87 to 98) among those who rece

31 cohort 1, SVR12 rates were 85% with 25 mg of velpatasvir, 96% with 25 mg of velpatasvir plus ribaviri

32 ohort 3, SVR12 rates were 100% with 25 mg of velpatasvir, 97% with 25 mg of velpatasvir plus ribaviri

33 Only velpatasvir and pibrentasvir had uniform high activity a

34 given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, i

35 patasvir plus ribavirin, 100% with 100 mg of velpatasvir, and 100% with 100 mg of velpatasvir plus ri

36 patasvir plus ribavirin, 100% with 100 mg of velpatasvir, and 96% with 100 mg of velpatasvir plus rib

37 lpatasvir plus ribavirin, 88% with 100 mg of velpatasvir, and 96% with 100 mg of velpatasvir plus rib

38 Four weeks of sofosbuvir, velpatasvir, and GS-9857 produced an SVR12 in 4 of 15 (2

39 reatment with the combination of sofosbuvir, velpatasvir, and GS-9857 produced an SVR12 in most treat

40 ledipasvir, ombitasvir, elbasvir, ruzasvir, velpatasvir, and pibrentasvir in cultured cells infected

41 ase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 i

42 ase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 i

43 ase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the protease inhibitor voxilaprevir (15

44 basvir, but equally sensitive to ombitasvir, velpatasvir, beclabuvir, dasabuvir, MK-3682, and sofosbu

45 Two patients receiving sofosbuvir-velpatasvir, both with HCV genotype 1, had a virologic r

46 ssigned in a 1:1 ratio to receive sofosbuvir-velpatasvir for 12 weeks (277 patients) or sofosbuvir-ri

47 In patients given sofosbuvir and velpatasvir for 12 weeks (n=90), clinically significant

48 udy evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with genotype 1, 2,

49 Once-daily sofosbuvir-velpatasvir for 12 weeks provided high rates of sustaine

50 Sofosbuvir-velpatasvir for 12 weeks was safe and provided high rate

51 ent with 400 mg of sofosbuvir plus 100 mg of velpatasvir for 12 weeks was well-tolerated and highly e

52 ir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks, but the 2 regimens had similar

53 asvir-voxilaprevir for 8 weeks or sofosbuvir-velpatasvir for 12 weeks.

54 re observed in patients given sofosbuvir and velpatasvir for 24 weeks (n=90).

55 t ribavirin for 12 weeks and with sofosbuvir-velpatasvir for 24 weeks resulted in high rates of susta

56 r plus ribavirin for 12 weeks, or sofosbuvir-velpatasvir for 24 weeks.

57 or 1200 mg) for 12 weeks, or sofosbuvir and velpatasvir for 24 weeks.

58 inhibitor sofosbuvir and the NS5A inhibitor velpatasvir for HCV in patients coinfected with HIV-1.

59 e-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not

60 ported in 15 patients (2%) in the sofosbuvir-velpatasvir group and none in the placebo group.

61 stained virologic response in the sofosbuvir-velpatasvir group was 95% (95% CI, 92 to 98), which was

62 stained virologic response in the sofosbuvir-velpatasvir group was 99% (95% confidence interval [CI],

63 mization but were assigned to the sofosbuvir-velpatasvir group.

64 sofosbuvir and ledipasvir or sofosbuvir and velpatasvir had decreased efficacy against infection wit

65 inhibitor sofosbuvir and the NS5A inhibitor velpatasvir in a once-daily, fixed-dose combination tabl

66 ssigned in a 1:1 ratio to receive sofosbuvir-velpatasvir, in a once-daily, fixed-dose combination tab

67 inhibitor sofosbuvir and the NS5A inhibitor velpatasvir once daily for 12 weeks, sofosbuvir-velpatas

68 All patients received sofosbuvir-velpatasvir once daily for 12 weeks.

69 ch cohort were randomly assigned to 25 mg of velpatasvir once daily with or without ribavirin or 100

70 daily with or without ribavirin or 100 mg of velpatasvir once daily with or without ribavirin.

71 hase 2 open-label trial, we found sofosbuvir-velpatasvir plus GS-9857 (8 weeks in treatment-naive pat

72 e found 8 weeks of treatment with sofosbuvir-velpatasvir plus GS-9857 to be safe and effective in tre

73 mg) once daily for 12 weeks, sofosbuvir and velpatasvir plus oral ribavirin (weight-based 1000 mg or

74 In patients given sofosbuvir and velpatasvir plus ribavirin (n=87), PRO scores decreased

75 patasvir once daily for 12 weeks, sofosbuvir-velpatasvir plus ribavirin for 12 weeks, or sofosbuvir-v

76 ng antiviral-based therapies with sofosbuvir-velpatasvir plus ribavirin for 24 weeks was well tolerat

77 with 25 mg of velpatasvir, 97% with 25 mg of velpatasvir plus ribavirin, 100% with 100 mg of velpatas

78 with 25 mg of velpatasvir, 96% with 25 mg of velpatasvir plus ribavirin, 100% with 100 mg of velpatas

79 with 25 mg of velpatasvir, 84% with 25 mg of velpatasvir plus ribavirin, 88% with 100 mg of velpatasv

80 of those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 18% of those who receive

81 ng those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 86% (95% CI, 77 to 92) a

82 0 mg of velpatasvir, and 100% with 100 mg of velpatasvir plus ribavirin.

83 00 mg of velpatasvir, and 96% with 100 mg of velpatasvir plus ribavirin.

84 00 mg of velpatasvir, and 96% with 100 mg of velpatasvir plus ribavirin.

85 of 8 weeks of treatment with sofosbuvir and velpatasvir plus the pangenotypic NS3/4A protease inhibi

86 inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologi

87 hosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic res

88 RBV-free pan-genotypic regimen with SOF and velpatasvir (SOF/VEL) on patient-reported outcomes (PROs

89 asvir-voxilaprevir to 12 weeks of sofosbuvir-velpatasvir using a noninferiority margin of 5%.

90 ssigned in a 1:1 ratio to receive sofosbuvir-velpatasvir-voxilaprevir (163 patients) or sofosbuvir-ve

91 interval [CI], 86-100) receiving sofosbuvir-velpatasvir-voxilaprevir alone and 24 of 25 (96%; 95% CI

92 e most commonly reported AEs with sofosbuvir-velpatasvir-voxilaprevir alone were diarrhea and bronchi

93 the rate of response was 98% with sofosbuvir-velpatasvir-voxilaprevir and 90% with sofosbuvir-velpata

94 assigned randomly to groups given sofosbuvir-velpatasvir-voxilaprevir for 8 weeks or sofosbuvir-velpa

95 ection, we did not establish that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to

96 4 infection were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group.

97 14 patients) were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group.

98 diarrhea and bronchitis; and with sofosbuvir-velpatasvir-voxilaprevir plus RBV were fatigue, anemia,

99 Sofosbuvir-velpatasvir-voxilaprevir taken for 12 weeks provided hig

100 None of the patients discontinued sofosbuvir-velpatasvir-voxilaprevir therapy because of an adverse e

101 the noninferiority of 8 weeks of sofosbuvir-velpatasvir-voxilaprevir to 12 weeks of sofosbuvir-velpa

102 A fixed-dose combination of sofosbuvir-velpatasvir-voxilaprevir was well tolerated and effectiv

103 fixed-dose combination tablet of sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin (RBV)

104 protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir).

105 d virologic response was 96% with sofosbuvir-velpatasvir-voxilaprevir, as compared with 0% with place

106 1a infection receiving 8 weeks of sofosbuvir-velpatasvir-voxilaprevir.

107 patients had an SVR to 8 weeks of sofosbuvir-velpatasvir-voxilaprevir; this did not meet the criterio

108 rug Administration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) fixed-do

109 response among patients receiving sofosbuvir-velpatasvir was 99% (95% confidence interval, 98 to >99)

110 Among these inhibitors, velpatasvir was more effective against variants with RAS

111 after antiviral therapy with sofosbuvir and velpatasvir, we found that intrahepatic MAIT cells are a

112 ish noninferiority to 12 weeks of sofosbuvir-velpatasvir, which produced an SVR in 98% of patients (9

113 n a fixed-dose combination of sofosbuvir and velpatasvir with and without ribavirin.

114 Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and w

115 plus the nonstructural protein 5A inhibitor velpatasvir with or without the nonstructural protein 3/

116 ated cirrhosis who were given sofosbuvir and velpatasvir without ribavirin.